S&P Futures
4,325.00 +10.25 (+0.24%) Dow Futures
33,939.00 +64.00 (+0.19%) Nasdaq Futures
14,746.25 +31.25 (+0.21%) Russell 2000 Futures
1,784.20 +6.30 (+0.35%) Crude Oil
91.37 +0.98 (+1.08%) Gold
1,914.30 -5.50 (-0.29%)
Azitra, Inc. (AZTR)
Chart Events
Performance Outlook
| Previous Close | 1.6900 |
| Open | 1.6300 |
| Bid | 0.0000 x 800 |
| Ask | 0.0000 x 1300 |
| Day's Range | 1.5100 - 1.6300 |
| 52 Week Range | 1.5100 - 5.1800 |
| Volume | |
| Avg. Volume | 15,036 |
| Market Cap | 18.388M |
| Beta (5Y Monthly) | N/A |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -1.2000 |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
Fair Value
Subscribe to Yahoo Finance Plus to view Fair Value for AZTR
Related Research
- Azitra IncAnalyst Report: Eli Lilly and CompanyEli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Jardiance, Trulicity, Humalog, and Humulin for diabetes; and Taltz and Olumiant for immunology.RatingFair ValueEconomic Moat6 days agoMorningstar
PR NewswireAzitra to Present at the H.C. Wainwright 25th Annual Global Investment Conference
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, announced today that Travis Whitfill, COO, will present an overview of the Company at the H.C. Wainwright 25th Annual Global Investment Conference, being held from September 11-13, 2023. Company management will also be participating in one-on-one meetings during the conference.
- PR Newswire
Azitra, Inc. Announces Second Quarter 2023 Financial Results and Business Updates
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today reported financial results for the second quarter ended June 30, 2023.
- PR Newswire
Azitra Adds Biotech Leaders Barbara Ryan and John Schroer to Its Board of Directors
Azitra, Inc. (NYSE American: AZTR), a clinical-stage biopharmaceutical company focused on developing innovative therapies for precision dermatology, today announced the addition of two members to its board of directors, Barbara Ryan and John Schroer.
